Wang Q, Gong LM, Zheng H. Effects of live
Clostridium butyricum tablets on intestinal flora balance,
toxic and side effects, and immune inflammatory indexes in colorectal cancer patients on postoperative FOLFOX4 chemotherapy.
Shijie Huaren Xiaohua Zazhi 2021;
29:435-442. [DOI:
10.11569/wcjd.v29.i8.435]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
BACKGROUND
Postoperative chemotherapy with FOLFOX4 regimen in patients with colorectal cancer destroys the normal digestion and metabolism of the body and reduces the immune capacity while removing and inhibiting cancer cells. As a beneficial bacterium, Clostridium butyricum can regulate the intestinal flora and enhance the immune function of the body, and can therefore be used to regulate the adverse reactions caused by chemotherapy to some extent.
AIM
To investigate the effect of live Clostridium butyricum tablets on intestinal flora balance, toxic and side effects, and immune inflammatory indexes in colorectal cancer patients on postoperative FOLFOX4 chemotherapy.
METHODS
From April 2017 to May 2020, 92 postoperative colorectal cancer patients treated at our hospital were selected and divided into a study group (n = 46) and a control group (n = 46) using simple randomization method. Both groups received FOLFOX4 chemotherapy after surgery, and the study group additionally received live Clostridium butyricum tablets. Each cycle of treatment was 2 weeks, and the treatment lasted for 8 weeks. Serum tumor markers [carbohydrate antigen 724 (CA724), carbohydrate antigen 199 (CA199), and carcinoembryonic antigen (CEA)], immune function indexes (CD4+ T cells, CD8+ T cells, and CD4+/CD8+ ratio), inflammatory response indexes [tumor necrosis factor-α (TNF-α), C-reactive protein (CRP), and interleukin-6 (IL-6)], intestinal flora indicators (Enterococcus faecalis, Escherichia coli, Lactobacillus, and Bifidobacterium), and intestinal mucosal barrier function indicators [D-lactic acid and fecal secretory immunoglobulin A (S-IgA)] were compared between the two groups before treatment and after 8 weeks of treatment. The incidence of side effects during treatment in the two groups was calculated.
RESULTS
After 8 weeks of treatment, serum CA724, CA199, and CEA levels were significantly lower in the study group than in the control group (P < 0.05); CD4+ T cells and CD4+/CD8+ ratio were significantly higher and CD8+ T cells were significantly lower than those of the control group (P < 0.05); serum levels of TNF-α, CRP, and IL-6 were significantly lower than those of the control group (P < 0.05); the numbers of Enterococcus faecalis, Lactobacillus, and Bifidobacterium were significantly higher and the number of Escherichia coli were significantly lower than those of the control group (P < 0.05); and plasma D lactic acid level was significantly lower and fecal S-IgA level was significantly higher than those of the control group (P < 0.05). The incidence of nausea and vomiting, numbness, leukopenia, and abnormal liver function in the study group was significantly lower than that of the control group (P < 0.05).
CONCLUSION
Live Clostridium butyricum tablets can correct intestinal flora disorders, repair the damaged intestinal mucosal barrier function, help regulate the immune inflammatory response, reduce the level of serum tumor markers, and reduce toxic and side effects in colorectal cancer patients on postoperative FOLFOX4 chemotherapy.
Collapse